The approach behind Amtagvi is a cell therapy conceived by Steve Rosenberg at the National Cancer Institute and has been in development since the late-1980s. The immune system is in constant surveillance and when cancer is detected, lymphocytes (white blood cells) traffic to the tumor to attack and destroy the cancer. The immune cells that enter the tumor are called Tumor Infiltrating Lymphocytes, or TIL, and will include T-cells that recognize distinctive tumor markers (neoantigens) on the cell surface of each person’s cancer. When cancer develops and prevails, the body’s natural TIL can no longer perform their intended function to fight the disease but can be harvested from the tumor and reactivated and reprogrammed as a drug.
About The Author
Iraj Ali has been CEO of Achilles Therapeutics since 2018. Previously he was a managing partner of Syncona Ltd. During his tenure at Syncona he served as...
The approval of the Iovance Biotherapeutics, Inc.'s product is a game changer for researchers and companies developing T-cell-based cancer treatments. (Also see "Iovance Lucks Out With Amtagvi" -...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?